Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - pancreatin - gastro-resistant capsule - pancreatin 300 mg - digestives, incl. enzymes

Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - pancreatin - gastro-resistant capsule - pancreatin 420 mg - digestives, incl. enzymes

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.); pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. - modified release capsule - 150 mg - active: pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide black iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. excipient: cetyl alcohol dimeticone ferrosoferric oxide gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.); pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u; pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u - modified release capsule - 300 mg - active: pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pancreatin 60.12mg (3,600 ph. eur. u/amylase, 5,000 ph. eur. u/lipase and 200 ph. eur. u/protease) - modified release granules - 60.12 mg - active: pancreatin 60.12mg (3,600 ph. eur. u/amylase, 5,000 ph. eur. u/lipase and 200 ph. eur. u/protease) excipient: cetyl alcohol dimeticone hypromellose phthalate macrogol 4000 triethyl citrate - for treatment of conditions associated with pancreatic exocrine insufficiency, such as: cystic fibrosis, chronic pancreatitis, post-pancreatectomy, post-gastrointestinal bypass surgery, e.g. billroth ii, gastroenterostomy; ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - pancreatin - capsules - pancreatin 150 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - pancreatic exocrine insufficiency.

Israel - English - Ministry of Health

abbott medical laboratories ltd, israel - pancreatin - capsules - pancreatin 300 mg - multienzymes (lipase, protease etc.) - multienzymes (lipase, protease etc.) - for the treatment of pancreatic exocrine insufficiency.

Canada - English - Health Canada

enzymatic therapy (canada) inc. - pancreatin (protease, amylase, lipase); papain; bromelain; chymotrypsin - tablet - 1625mg; 25mg; 25mg; 1mg - pancreatin (protease, amylase, lipase) 1625mg; papain 25mg; bromelain 25mg; chymotrypsin 1mg - digestants

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - pancreatin 314.65mg - 350.175mg ((25000u lipase, 22500u amylase, 1250u protease)) - modified release capsule - active: pancreatin 314.65mg - 350.175mg ((25000u lipase, 22500u amylase, 1250u protease)) excipient: colloidal silicon dioxide crospovidone gelatin   glycol montanate iron oxide black iron oxide red magnesium stearate methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose purified talc simeticone titanium dioxide triethyl citrate erythrosine gelatin   patent blue v - panzytrat is indicated for patients with exocrine pancreatic enzyme deficiency such as (but not restricted to): · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery e.g. billroth ii gastroenterostomy · ductal obstructions from neoplasm e.g. of the pancreas or common bile duct

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - pancreatin - gastro-resistant capsule, hard - 25000 - enzyme preparations; multienzymes (lipase, protease etc.)